BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Davutamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Davutamig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04077099-2702@assetmemo.bio
DTSTAMP:20261121T005556Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Davutamig: Phase 1/2 readout est. (NCT04077099)
DESCRIPTION:Davutamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition 
 Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer\nEstimated primar
 y completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/davutamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04077099
URL:https://assetmemo.bio/drug/davutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
